VasoDynamics submits UK Clinical Trial Application for NG11-2
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
21st October 2022 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has today submitted a detailed Clinical Trial Application for their Phase-1b clinical trial, using the new IRAS “Combined Ways of Working” process introduced by UK HRA/MHRA in 2022 to expedite Clinical Trial Approvals. The study will investigate the safety and preliminary effect of NG11-2 mouthwash of reducing or preventing the development of severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for their Head & Neck cancer, for which there is currently no approved treatment.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“Following the successful completion of a scientific advisory meeting last September, we have further developed and optimised the Phase-1b clinical study protocol with strong support from our clinical investigators and positive engagement with relevant patients’ groups. It is a key milestone in the development of our NG11 oral topical platform. We are looking forward to the feedback from HRA/MHRA to move this exciting product into a clinical trial at 5-6 major NHS oncology centres across the UK.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.
